Citigroup’s Loncar China BioPharma ETF CHNA Stock Holding History

Citigroup’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-390	Closed	-$9K	–	7729
2020 Q1	$9K	Hold	390	–	–	﹤0.01%	7099
2019 Q4	$10K	Buy	+390	New	+$9.28K	﹤0.01%	7219

Other funds holding CHNA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's CHNA Position: Q2 2020 in Review

Citigroup sold out of Loncar China BioPharma ETF (CHNA) in Q2 2020, closing a stake of 390 shares — an estimated $9K sold.

Citigroup first reported a position in CHNA in Q4 2019 and held it in 2 quarters. The position peaked at $10K in Q4 2019. 3 funds tracked by Wall St. Rank hold CHNA as of Q2 2020.

Citigroup reported no remaining Loncar China BioPharma ETF position as of Q2 2020 after selling out during the quarter.
Citigroup sold 390 Loncar China BioPharma ETF shares in Q2 2020, an estimated $9K.
Citigroup first reported a position in Loncar China BioPharma ETF in Q4 2019 and held it in 2 quarters.
Citigroup's Loncar China BioPharma ETF position peaked at $10K in Q4 2019.
3 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q2 2020.

Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.